F-star is a clinical-stage biopharmaceutical company developing tetravalent bispecific antibodies for a paradigm-shift in cancer therapy. By developing medicines that seek to block tumor immune evasion, the Company's goal is to offer patients greater and more durable benefits than current immuno-oncology treatments. Through its proprietary tetravalent, bispecific natural antibody (mAb²™) format, F-star's mission is to generate highly differentiated best-in-class drug candidates with monoclonal antibody-like manufacturability.
Company profile
Ticker
FSTX
Exchange
Website
CEO
Eliot Richard Forster
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Spring Bank Pharmaceuticals, Inc.
SEC CIK
Corporate docs
Subsidiaries
SBP Securities Corporation • F-star Therapeutics Limited ...
FSTX stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
20 Mar 23
EFFECT
Notice of effectiveness
14 Mar 23
EFFECT
Notice of effectiveness
14 Mar 23
EFFECT
Notice of effectiveness
14 Mar 23
EFFECT
Notice of effectiveness
14 Mar 23
EFFECT
Notice of effectiveness
14 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
9 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
9 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
9 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
9 Mar 23
Latest ownership filings
Financial summary
Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 35.57 mm | 35.57 mm | 35.57 mm | 35.57 mm | 35.57 mm | 35.57 mm |
Cash burn (monthly) | 5.80 mm | 2.96 mm | 6.14 mm | 3.76 mm | 5.52 mm | 3.16 mm |
Cash used (since last report) | 108.04 mm | 55.10 mm | 114.33 mm | 70.13 mm | 102.78 mm | 58.87 mm |
Cash remaining | -72.47 mm | -19.53 mm | -78.76 mm | -34.56 mm | -67.21 mm | -23.30 mm |
Runway (months of cash) | -12.5 | -6.6 | -12.8 | -9.2 | -12.2 | -7.4 |
Institutional ownership, Q1 2023
12.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 6 |
Opened positions | 0 |
Closed positions | 63 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 9.40 mm |
Total shares | 2.70 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
GSK GSK | 803.92 k | $973.00 k |
Cooperatieve AESCAP Venture I U.A. | 615.64 k | $4.09 mm |
Atlas Venture Opportunity Fund I | 599.52 k | $3.01 mm |
Atlas Venture Fund VII L P | 575.00 k | $696.00 k |
MKGAF Merck KGaA | 75.14 k | $377.00 k |
Biotechnology Value Fund L P | 25.84 k | $255.00 k |
Beryl Capital Management | 0.00 | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
8 Mar 23 | Nessan Bermingham | Common Stock | Sale back to company | Dispose D | No | No | 7.12 | 6,328 | 45.06 k | 0 |
8 Mar 23 | Nessan Bermingham | Common Stock | Dispose U | No | No | 7.12 | 97,547 | 694.53 k | 6,328 | |
8 Mar 23 | Nessan Bermingham | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 3.41 | 20,000 | 68.20 k | 0 |
8 Mar 23 | Nessan Bermingham | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 6.88 | 20,000 | 137.60 k | 0 |
8 Mar 23 | Nessan Bermingham | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 16.62 | 34,111 | 566.92 k | 0 |
8 Mar 23 | Edward Benz JR | Common Stock | Sale back to company | Dispose D | No | No | 7.12 | 4,385 | 31.22 k | 0 |
8 Mar 23 | Edward Benz JR | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 3.41 | 20,000 | 68.20 k | 0 |
8 Mar 23 | Edward Benz JR | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 6.88 | 20,000 | 137.60 k | 0 |
8 Mar 23 | Edward Benz JR | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 14.31 | 3,937 | 56.34 k | 0 |
8 Mar 23 | Geoffrey Race | Common Stock | Dispose U | No | No | 7.12 | 3,937 | 28.03 k | 0 |